Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - probenecid, quantity: 500 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate; stearic acid; magnesium stearate; maize starch; microcrystalline cellulose; povidone; macrogol 8000; hypromellose; macrogol 400; titanium dioxide; sunset yellow fcf; polysorbate 80; quinoline yellow - indications as at 25 may 2000 : gout - probenecid is a uricosuric agent for the treatment of hyperuricaemia in all stages of gout and gouty arthritis except an acute attack. asymptomatic hyperuricaemia seems to occur in a significant percentage of relatives of gouty patients. probenecid may be given prophylactically to these people to forestall gouty attacks and urate deposition in tissues. by virtue of its effective uricosuric activity, probenecid may be used to control the hyperuricaemia induced or aggravated by many diuretics employed for the treatment of oedema and hypertension (e.g. thiazides and smiliar diuretics). b-lactam antibiotic therapy - probenecid is indicated for the elevation and prolongation of plasma levels by whatever route the antibiotic is given. a two-to-fourfold increase in plasma levels has been demonstrated for benzylpenicillin, phenoxymethylpenicillin, the synthetic penicillins, ampicillin, methicillin, oxacillin, cloxacillin, nafcillin, carbenicillin, and for the cephamycin, mefoxin (cefoxitin sodium, msd), and the cephalosporins, cephalothin, cephalexin and cephaloglycin. because of its mechanisim of action, probenecid is not recommended in conjunction with a b-lactam antibiotic in the presence of known renal impairment. concurrent treatment with cidofovir for cmv retinitis in hiv patients. probenecid is recommended to be administered concomitantly with cidofovir, as the combination reduces the potential for nephrotoxicity associated with cidofovir.

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals nj, llc - probenecid (unii: po572z7917) (probenecid - unii:po572z7917) - probenecid 500 mg

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - probenecid (unii: po572z7917) (probenecid - unii:po572z7917) - probenecid tablets are indicated for the treatment of the hyperuricemia associated with gout and gouty arthritis. as an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given. hypersensitivity to probenecid. children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid should not be started until an acute gouty attack has subsided.

United States - English - NLM (National Library of Medicine)

medstone pharma llc - probenecid (unii: po572z7917) (probenecid - unii:po572z7917) - probenecid tablets are indicated for the treatment of the hyperuricemia associated with gout and gouty arthritis. as an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given. hypersensitivity to probenecid. children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid should not be started until an acute gouty attack has subsided.

United States - English - NLM (National Library of Medicine)

quality care products, llc - probenecid (unii: po572z7917) (probenecid - unii:po572z7917) - probenecid tablets are indicated for the treatment of the hyperuricemia associated with gout and gouty arthritis. as an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given. hypersensitivity to probenecid. children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid should not be started until an acute gouty attack has subsided.

United States - English - NLM (National Library of Medicine)

rising pharma holdings, inc. - probenecid (unii: po572z7917) (probenecid - unii:po572z7917) - probenecid tablets are indicated for the treatment of the hyperuricemia associated with gout and gouty arthritis. as an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given. hypersensitivity to probenecid. children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid should not be started until an acute gouty attack has subsided.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - probenecid (unii: po572z7917) (probenecid - unii:po572z7917) - probenecid tablets are indicated for the treatment of the hyperuricemia associated with gout and gouty arthritis. as an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given. hypersensitivity to probenecid. children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid should not be started until an acute gouty attack has subsided.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - probenecid 500mg - film coated tablet - 500 mg - active: probenecid 500mg excipient: colloidal silicon dioxide magnesium stearate opadry yellow ys-1-2135 powdered cellulose sodium laurilsulfate sodium starch glycolate

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - probenecid (unii: po572z7917) (probenecid - unii:po572z7917) - for treatment of the hyperuricemia associated with gout and gouty arthritis. as an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given. hypersensitivity to probenecid. children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid should not be started until an acute gouty attack has subsided.

United States - English - NLM (National Library of Medicine)

westminster pharmaceuticals, llc - probenecid (unii: po572z7917) (probenecid - unii:po572z7917) - for treatment of the hyperuricemia associated with gout and gouty arthritis. as an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given. hypersensitivity to probenecid. children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid should not be started until an acute gouty attack has subsided.